TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with arginine deiminase

This publication has 52 references indexed in Scilit:

• Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2011
• Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours
  British Journal of Cancer, 2011
• New insights into apoptosis signaling by Apo2L/TRAIL
  Oncogene, 2010
• The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines
  Biochemical and Biophysical Research Communications, 2010
• Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2010
• Is TRAIL the holy grail of cancer therapy?
  Apoptosis, 2009
• To kill a tumor cell: the potential of proapoptotic receptor agonists
  Journal of Clinical Investigation, 2008
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily
  Nature Reviews Cancer, 2002
• Safety and antitumor activity of recombinant soluble Apo2 ligand
  Journal of Clinical Investigation, 1999
• Arginine Deiminase Inhibits Cell Proliferation by Arresting Cell Cycle and Inducing Apoptosis
  Biochemical and Biophysical Research Communications, 1999